Advertisement
Australia markets closed
  • ALL ORDS

    8,153.70
    +80.10 (+0.99%)
     
  • ASX 200

    7,896.90
    +77.30 (+0.99%)
     
  • AUD/USD

    0.6518
    -0.0018 (-0.28%)
     
  • OIL

    83.17
    +1.82 (+2.24%)
     
  • GOLD

    2,241.90
    +29.20 (+1.32%)
     
  • Bitcoin AUD

    108,547.16
    +3,047.31 (+2.89%)
     
  • CMC Crypto 200

    885.54
    0.00 (0.00%)
     
  • AUD/EUR

    0.6037
    +0.0007 (+0.11%)
     
  • AUD/NZD

    1.0904
    +0.0024 (+0.22%)
     
  • NZX 50

    12,105.29
    +94.63 (+0.79%)
     
  • NASDAQ

    18,249.40
    -31.44 (-0.17%)
     
  • FTSE

    7,952.62
    +20.64 (+0.26%)
     
  • Dow Jones

    39,778.48
    +18.40 (+0.05%)
     
  • DAX

    18,492.49
    +15.40 (+0.08%)
     
  • Hang Seng

    16,541.42
    +148.58 (+0.91%)
     
  • NIKKEI 225

    40,168.07
    -594.66 (-1.46%)
     

Strength Seen in Treace Medical Concepts (TMCI): Can Its 8.4% Jump Turn into More Strength?

Treace Medical Concepts TMCI shares ended the last trading session 8.4% higher at $23.53. The jump came on an impressive volume with a higher-than-average number of shares changing hands in the session. This compares to the stock's 11.7% gain over the past four weeks.

Treace Medical Concepts scored a strong price rise on investors’ optimism surrounding its impressive top-line results. The company reported revenue growth of 45% in the second quarter, and 50% in the first half of 2022. According to management, the company exhibited continued gains in key operating metrics led by the underlying strength of its business and effective execution of commercial strategies. The Zacks Consensus Estimate for the company’s full-year 2022 revenues is pegged at $132.4 million, suggesting an increase of 40.2% on a year over year basis.

This orthopedic medical device maker is expected to post quarterly loss of $0.28 per share in its upcoming report, which represents a year-over-year change of -133.3%. Revenues are expected to be $30.1 million, up 39.2% from the year-ago quarter.

Earnings and revenue growth expectations certainly give a good sense of the potential strength in a stock, but empirical research shows that trends in earnings estimate revisions are strongly correlated with near-term stock price movements.

ADVERTISEMENT

For Treace Medical Concepts, the consensus EPS estimate for the quarter has been revised 26.9% lower over the last 30 days to the current level. And a negative trend in earnings estimate revisions doesn't usually translate into price appreciation. So, make sure to keep an eye on TMCI going forward to see if this recent jump can turn into more strength down the road.

The stock currently carries a Zacks Rank #3 (Hold). You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>

Treace Medical Concepts is part of the Zacks Medical - Instruments industry. Avanos Medical AVNS, another stock in the same industry, closed the last trading session 2.7% higher at $25.42. AVNS has returned -12.6% in the past month.

For Avanos Medical , the consensus EPS estimate for the upcoming report has changed -5.9% over the past month to $0.36. This represents a change of +44% from what the company reported a year ago. Avanos Medical currently has a Zacks Rank of #4 (Sell).


Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
 
Treace Medical Concepts, Inc. (TMCI) : Free Stock Analysis Report
 
AVANOS MEDICAL, INC. (AVNS) : Free Stock Analysis Report
 
To read this article on Zacks.com click here.
 
Zacks Investment Research